
Recently, Suven Pharmaceuticals , a leading pharma company in India, announced its merger with Cohance Life Sciences. This move comes a year after Advent, a leading global private equity, acquired a majority stake in Suven back in December 2022. The merger is based on a share swap agreement, where for every 295 shares of Cohance, shareholders will be issued 11 shares of Suven Pharma. As a result, Advent will increase its stake to 66.7 per cent. This transaction will be completed in the next 12-15 months. Suven Pharma and Cohance: A brief Suven Pharma is one of the largest pharmaceutical companies in the world. It primarily focuses on CDMO (contract development and manufacturing), custom synthesis and more. As of the nine months ending FY24, the company earned 56 per cent of its revenue from CDMO, 27 per cent from specialty chemicals and the remaining 17 per cent from formulations and other products. Cohance, too, is involved in the production of CDMO and API. It provides end-to-end CDMO services to clients across 60 countries. As of the nine months ending FY24, Cohance generated 68 per cent of its revenue from APIs and the remaining 32 per cent from CDMO. Why is the merger taking place? The move is expected to strengthen the position of t





